RPRX vs. LLY

Last updated Jun 4, 2026

RPRX (Royalty Pharma plc) and LLY (Eli Lilly and Company) are both stocks. Both are in the Healthcare sector — RPRX in Biotechnology, LLY in Drug Manufacturers - General. Over the past 5 years, RPRX returned 6.45%/yr vs 41.13%/yr for LLY. At a 0.24 correlation, their price movements are largely independent.

Performance

RPRX vs. LLY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Royalty Pharma plc (RPRX) and Eli Lilly and Company (LLY). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, RPRX achieves a 43.64% return, which is significantly higher than LLY's 0.72% return.

RPRX

• 1D: 1.78%
• 1M: 9.99%
• YTD: 43.64%
• 6M: 40.16%
• 1Y: 68.67%
• 3Y*: 21.21%
• 5Y*: 6.45%
• 10Y*: —

LLY

• 1D: 1.37%
• 1M: 11.64%
• YTD: 0.72%
• 6M: 4.73%
• 1Y: 44.70%
• 3Y*: 35.56%
• 5Y*: 41.13%
• 10Y*: 32.66%

*Multi-year figures are annualized to reflect compound growth (CAGR)

RPRX vs. LLY - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
RPRX Royalty Pharma plc	43.64%	55.29%	-6.36%	-27.08%	0.99%	-19.09%	13.33%
LLY Eli Lilly and Company	0.72%	40.25%	33.30%	60.91%	34.26%	66.08%	4.17%

Correlation

The correlation between RPRX and LLY is 0.32, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.32
Correlation (3Y) Calculated over the trailing 3-year period	0.19
Correlation (5Y) Calculated over the trailing 5-year period	0.26
Correlation (All Time) Calculated using the full available price history since Jun 17, 2020	0.24

The correlation between RPRX and LLY shifts across timeframes, from 0.19 (3 years) to 0.32 (1 year), reflecting how their relationship changes across market environments.

Fundamentals

EPS RPRX : $1.97 LLY : $28.14
PE Ratio RPRX : 27.92 LLY : 38.33
PEG Ratio RPRX : 0.03 LLY : 0.77
PS Ratio RPRX : 9.47 LLY : 13.41
Total Revenue (TTM) RPRX : $2.44B LLY : $72.25B
Gross Profit (TTM) RPRX : $1.81B LLY : $59.75B
EBITDA (TTM) RPRX : $1.70B LLY : $32.97B

Return for Risk

RPRX vs. LLY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RPRX

RPRX Risk / Return Rank: 95
RPRX Sharpe Ratio Rank: 95
RPRX Sortino Ratio Rank: 94
RPRX Omega Ratio Rank: 94
RPRX Calmar Ratio Rank: 97
RPRX Martin Ratio Rank: 96

LLY

LLY Risk / Return Rank: 72
LLY Sharpe Ratio Rank: 75
LLY Sortino Ratio Rank: 70
LLY Omega Ratio Rank: 71
LLY Calmar Ratio Rank: 73
LLY Martin Ratio Rank: 74

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RPRX vs. LLY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Royalty Pharma plc (RPRX) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	RPRX	LLY	Difference
Sharpe ratio Return per unit of total volatility	3.17	1.19	+1.99
Sortino ratio Return per unit of downside risk	3.94	1.75	+2.20
Omega ratio Gain probability vs. loss probability	1.53	1.24	+0.29
Calmar ratio Return relative to maximum drawdown	9.35	1.90	+7.45
Martin ratio Return relative to average drawdown	23.50	4.73	+18.78
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

RPRX vs. LLY - Sharpe Ratio Comparison

The current RPRX Sharpe Ratio is 3.17, which is higher than the LLY Sharpe Ratio of 1.19. The chart below compares the historical Sharpe Ratios of RPRX and LLY, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	RPRX	LLY	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	3.17	1.19	+1.99
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.27	1.26	-0.99
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	1.09	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.22	0.57	-0.35

Drawdowns

RPRX vs. LLY - Drawdown Comparison

The maximum RPRX drawdown since its inception was -49.68%, smaller than the maximum LLY drawdown of -68.24%. Use the drawdown chart below to compare losses from any high point for RPRX and LLY.

Drawdown Indicators

	RPRX	LLY	Difference
Max Drawdown Largest peak-to-trough decline	-49.68%	-68.24%	+18.56%
Max Drawdown (1Y) Largest decline over 1 year	-7.38%	-23.64%	+16.26%
Max Drawdown (3Y) Largest decline over 3 years	-26.46%	-34.48%	+8.02%
Max Drawdown (5Y) Largest decline over 5 years	-43.44%	-34.48%	-8.96%
Max Drawdown (10Y) Largest decline over 10 years	—	-34.48%	—
Current Drawdown Current decline from peak	-1.42%	-4.26%	+2.84%
Average Drawdown Average peak-to-trough decline	-26.44%	-19.22%	-7.22%
Ulcer Index Depth and duration of drawdowns from previous peaks	2.93%	9.49%	-6.56%

Volatility

RPRX vs. LLY - Volatility Comparison

The current volatility for Royalty Pharma plc (RPRX) is 6.08%, while Eli Lilly and Company (LLY) has a volatility of 9.16%. This indicates that RPRX experiences smaller price fluctuations and is considered to be less risky than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	RPRX	LLY	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.08%	9.16%	-3.08%
Volatility (6M) Calculated over the trailing 6-month period	14.04%	26.81%	-12.77%
Volatility (1Y) Calculated over the trailing 1-year period	21.75%	37.88%	-16.13%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	23.92%	32.79%	-8.87%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	26.87%	30.14%	-3.27%

Dividends

RPRX vs. LLY - Dividend Comparison

RPRX's dividend yield for the trailing twelve months is around 1.66%, more than LLY's 0.60% yield.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
LLY Eli Lilly and Company	0.60%	0.56%	0.67%	0.78%	1.07%	1.23%	1.75%	1.96%	1.94%	2.46%	2.77%	2.37%
RPRX Royalty Pharma plc	1.66%	2.28%	3.29%	2.85%	1.92%	1.71%	0.60%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials

RPRX vs. LLY - Profitability Comparison

The chart below illustrates the profitability comparison between Royalty Pharma plc and Eli Lilly and Company over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

RPRX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Royalty Pharma plc reported a gross profit of 0.00 and revenue of 631.00M. Therefore, the gross margin over that period was 0.0%.

LLY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Eli Lilly and Company reported a gross profit of 15.64B and revenue of 19.80B. Therefore, the gross margin over that period was 79.0%.

RPRX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Royalty Pharma plc reported an operating income of 563.00M and revenue of 631.00M, resulting in an operating margin of 89.2%.

LLY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Eli Lilly and Company reported an operating income of 9.19B and revenue of 19.80B, resulting in an operating margin of 46.4%.

RPRX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Royalty Pharma plc reported a net income of 295.00M and revenue of 631.00M, resulting in a net margin of 46.8%.

LLY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Eli Lilly and Company reported a net income of 7.40B and revenue of 19.80B, resulting in a net margin of 37.4%.

Frequently Asked Questions

Can I hold both RPRX and LLY in my portfolio?

RPRX and LLY have a correlation of 0.32, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, RPRX or LLY?

LLY has higher volatility (9.16%) compared to RPRX (6.08%). In terms of maximum drawdown, RPRX dropped -49.68% vs LLY's -68.24%.

Which has better risk-adjusted returns?

RPRX currently has the higher Sharpe Ratio (3.17 vs 1.19), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.